Compare GROV & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | CALC |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 19.1M |
| IPO Year | 2021 | 2020 |
| Metric | GROV | CALC |
|---|---|---|
| Price | $1.06 | $1.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 67.4K | 62.0K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $0.44 |
| 52 Week High | $1.57 | $7.20 |
| Indicator | GROV | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 46.84 |
| Support Level | $0.99 | $0.51 |
| Resistance Level | $1.15 | $2.31 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 58.71 | 3.85 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.